The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can
improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled
hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin
Receptor Blocker (ARB).The safety of this treatment will also be studied

- Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks [12 wks for
Thiazolidinedione (TZD)] or a stable daily dose of insulin, as a monotherapy or in
combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1
additional antihypertensive medication for at least 4 weeks